Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company developing genetically engineered allogeneic CAR T cell therapies for cancer and autoimmune diseases. Its off-the-shelf T cell products, derived from healthy donors, target antigens like CD19 and CD70 to treat hematologic malignancies, solid tumors, and autoimmune disorders. The company’s platform emphasizes scalable manufacturing, reduced graft-versus-host disease risk, and faster patient access compared to autologous therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.